Consecutive Vs. Non-Consecutive Stereotactic Body Radiotherapy For Early Stage Non-Small Cell Lung Cancer
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 20
- 试验地点
- 4
- 主要终点
- Two year control measured by PET (positron emission tomography) scan
研究概览
简要总结
The purpose of this study is to determine if stereotactic body radiotherapy (SBRT) on non-consecutive days will increase the chances of curing non-small cell lung cancer when compared to daily treatment.
详细描述
The purpose of this study is to determine if treatment with stereotactic body radiotherapy (SBRT) on non-consecutive days will improve the chance of curing non-small cell lung cancer compared to treatment with SBRT on consecutive days. In either case, the dose of radiation is the same. Non-consecutive treatments will be at least 40 hours apart and no more than 100 hours apart. The total course of treatment will be 8-12 days. Consecutive treatments will be daily over 4-5 days within one calendar week. The total course of treatment will be 4-5 days.
The study team will assess if DNA from the tumor can be found in the blood to determine which patients respond quickest to radiotherapy. These results will not be made available to participants and will not change treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 18 years of age (no upper age limit).
- •A diagnosis of non-small cell lung cancer, T1-2 N0 M0 either with histologic confirmation or with documented interval growth of the index lesion on two interval computed tomography (CT) chest scans and an SUVmax of the lesion ≥ 3.0 on a pretreatment PET scan.
- •Patient must be deemed medically inoperable or refuse surgery.
- •Radiographic evaluation of the mediastinum and distant sites with a CT scan of the chest and PET scan.
- •For T2b N0 patients, radiographic evaluation of the brain with magnetic resonance imaging (MRI) of the brain unless the patient has contraindications to an MRI scan (in which case a CT scan of the head is necessary).
- •For central T1 N0 and all T2 N0 patients, pathologic sampling (either via endobronchial ultrasound-guided biopsy [EBUS] or mediastinoscopy) of mediastinal lymph nodes is required.
- •ECOG Performance Status 0-
- •For women of childbearing potential, negative pregnancy test within 2 weeks prior to SBRT treatment.
- •Patients must be deemed able to comply with the treatment plan and follow-up schedule.
- •Patients must provide specific informed consent prior to study entry.
- •Women of childbearing potential and male participants who are sexually active must use adequate contraception during treatment and for 6 weeks following treatment.
排除标准
- •Prior history of radiation therapy to the thorax that would likely increase the risk of serious complications from the radiotherapy delivered on this protocol.
- •Prior history of lung cancer.
- •Currently taking disease-modifying rheumatoid drugs (DMRDs).
- •Severe, active co-morbidity, defined as follows:
- •Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
- •Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects. Note, however, that coagulation parameters are not required for entry into this protocol.
- •Prior organ transplant.
- •Systemic lupus.
- •Psoriatic arthritis.
- •Known to be HIV positive. HIV-positive patients are known to have worse clinical outcomes, especially for local, regional, and distant cancer control. This poorer prognosis is thought to be secondary to a compromised immune system.
结局指标
主要结局
Two year control measured by PET (positron emission tomography) scan
时间窗: Two years
Control defined as PET imaging with uptake of a similar intensity as the pretreatment staging PET
Two-year control measured by CT (computerized tomography) scan
时间窗: Two years
Control defined as Less than 20% increase in the largest dimension of treated tumor measurable by CT
次要结局
- Document patient-reported quality of life before, during, and after treatment(2 years)
- Document acute and late toxicity related to treatment(2 years)
- Evaluate circulating tumor DNA(2 years)
- Overall Survival(2 years)
- Progression Free Survival(2 years)